Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
2
33%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Tdap Vaccine Safety for Plasma Donors

NCT04142983
completedphase_4

Adacel® Booster Vaccination for CMI Assay Development

NCT04543669
completedphase_3

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970
completed

2-year Follow-up After a Single Dose Acellular Pertussis Vaccination

NCT04113655
completed

3-year Follow-up After a Single Dose Acellular Pertussis Vaccination

NCT04102137
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04142983Phase 2

Tdap Vaccine Safety for Plasma Donors

Completed
NCT04543669Phase 4

Adacel® Booster Vaccination for CMI Assay Development

Completed
NCT00489970Phase 3

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Completed
NCT04113655

2-year Follow-up After a Single Dose Acellular Pertussis Vaccination

Completed
NCT04102137

3-year Follow-up After a Single Dose Acellular Pertussis Vaccination

Completed
NCT00346073Phase 3

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6